Clinical Disorders Overview

Principles

Definition

Clinical disorders is an academic and research domain dedicated to the systematic study, classification, diagnosis, etiology, and treatment of patterns of thought, emotion, or behavior that deviate significantly from normative functioning and are associated with distress or impairment. This field investigates the biological, psychological, and social factors underlying these conditions to advance understanding, improve clinical practice, and inform public health initiatives.

Ontological type

Treatment Modalities

Classification Systems

Etiological Models

Key developments

Key Figures

Biological Psychiatry Consolidation era

During the Biological Psychiatry Consolidation era, clinical disorders were increasingly understood through brain mechanisms, with neurochemical and neuroendocrine substrates guiding diagnosis and treatment. Henri Laborit and, in parallel, Pierre Deniker and Jean Delay demonstrated chlorpromazine's antipsychotic effects in the early 1950s, inaugurating pharmacologic treatment and shifting practice toward mechanistic explanations. Arvid Carlsson's work on dopamine in the 1950s–60s provided a neurochemical basis for psychosis and helped crystallize the dopamine hypothesis of schizophrenia. John Cade's discovery of lithium for mania, together with neuropharmacologists such as Julius Axelrod and Solomon H. Snyder who clarified transmitter release, reuptake, and receptor action, anchored a biomarker- and psychopharmacology-driven program across clinical disorders.

Biopsychosocial Diagnostic Consolidation era

Shelley E. Taylor [1] is a leading figure whose work spanned major centers such as the University of California, Los Angeles [2] and the University of Pittsburgh [3]. Her key contribution is the 'Tend and Befriend' [4] framework, which reframes stress responses to emphasize social buffering and caregiving, integrating psychosocial processes with neurobiological pathways. Taylor [1] has further emphasized translating psychosocial stress models into neurobiological and clinical outcomes. Taylor [1]'s contributions helped bridge population epidemiology with standardized rating scales and nosologies that guided decision-making in practice and policy.

Neuroimmune Precision Psychiatry era

Bradley F. Boeve [1] is affiliated with the University Memory and Aging Center [3] and Harvard University [4] during this era. His key contributions center on the multicentre paper 'Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study' [6], which identified early risk factors and clinical predictors for progression, providing a framework for mechanism-based prognosis in heterogeneous REM sleep behaviour disorders. Brit Mollenhauer [2] is affiliated with Harvard University [4] and The University of Texas Southwestern Medical Center [5] during this era. Her contributions similarly emphasize the multicentre REM sleep behaviour disorder study [6], advancing risk-stratified classification and prognosis in neuroimmune precision psychiatry.